search
Back to results

Clinical Trial of Allogenic Adipose Tissue-Derived Mesenchymal Progenitor Cells Therapy for Knee Osteoarthritis

Primary Purpose

Osteoarthritis

Status
Completed
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
Mesenchymal progenitor cells
Sponsored by
Cellular Biomedicine Group Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Osteoarthritis

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Object has an allergic history or is of an allergic constitution.
  • Subjects who understand and sign the consent form for this study.
  • Age: 18-70, males and females.
  • Clinical diagnosis of degenerative arthritis by Radiographic Criteria of KellgrenLawrence:Duration of pain over Grade 4(11-point numeric scale)> 4 months.
  • Course of Knee osteoarthritis:6 months to 10 years;
  • The VAS score :3-8 points.(the data acquisition time is to stop using all analgesic at least 3 days ).

Exclusion Criteria:

  • The subject has an allergic history of medicine or food。.
  • The subject'BMI is over 30.
  • The subject has uncontrolled or hard-to-control diseases of cardiovascular, liver, kidney or lung, endocrine system.
  • The subject has an history malignant tumour.
  • The subject has complications or diseases of: systemic or rheumatoid arthritis, Chondrocalcinosis articularis, Hemochromatosis,inflammatory arthropathy,avascular necrosis of femoral head,Paget's disease,hemophilic arthropathy,infectional arthritis,Charcot's disease,villonodular synovitis or synovial chondromatosis.
  • The subject has severe generalized infectious diseases or local knee infection in the 3 months prior to this trial.
  • The subject has disease of lower limbs which may be interfered knee evaluation, for example fibromyalgia, osphyalgia, lumbar disc protrusion and so on.
  • The subject has coagulation disorders.
  • The subject has received arthroscopic surgery or intra-articular operations in the 6 months prior to this trial.
  • The subject has received other intra-articular injections for KOA in the 6 months preceding the trial.
  • The subject has received aminoglucose or chondroitin sulfate in the 6 months preceding the trial.
  • The subject has plan of knee prosthesis within the trial.
  • The subject has contraindication of MRI, included but not only: the subject installed heart pacemaker、defibrillator、heart bracket、heart valve prosthesis、metal clip after aneurysm surgery、drug infusion device implanted in vivo、any electronic device implanted in the body(nerve stimulator、bone growth stimulator)、endovascular coil、strainer、ECG monitor、metal suture、shrapnel or sand of body, plate fixation and steel nail after fracture

    - Page 4 of 4 [DRAFT] - surgery、artificial limb or joint、audiphone、artificial cochlea、middle ear shift plant、metallic intraocular foreign body etc; claustrophobia、pregnancy within 3 months、critically ill patients.

  • The subject tests positive for: HIV, hepatitis virus, syphilis or other infectious diseases.
  • The subject has history of alcoholism, drug abuse, or mental illness in the 3 years prior to this trial.
  • The subject has participated in any other clinical trial in the 3 months prior to this trial.
  • The subject is pregnant, lactating or planning to conceive within the next 6 months.
  • The subject has any other unsuitable or adverse condition to be determined by the investigator.

Sites / Locations

  • Department of Rheumatology,Ren Ji Hospital,School of Medicine,Shanghai Jiao Tong University,Shanghai,China

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Other

Other

Other

Arm Label

Mesenchymal progenitor cells Dosage 1

Mesenchymal progenitor cells Dosage 2

Mesenchymal progenitor cells Dosage 3

Arm Description

Mesenchymal progenitor cells low-dose group

Mesenchymal progenitor cells mid-dose group

Mesenchymal progenitor cells high-dose group

Outcomes

Primary Outcome Measures

Safety, recording of Adverse Events and Serious Adverse Events
WOMAC Score

Secondary Outcome Measures

VAS Score
SF-36
The volume of articular cartilage
WORMS Score

Full Information

First Posted
December 21, 2015
Last Updated
September 12, 2018
Sponsor
Cellular Biomedicine Group Ltd.
Collaborators
RenJi Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT02641860
Brief Title
Clinical Trial of Allogenic Adipose Tissue-Derived Mesenchymal Progenitor Cells Therapy for Knee Osteoarthritis
Official Title
A Phase I, Randomized, Single-centered, Double-blinded Clinical Trial of Allogenic Adipose Tissue-Derived Mesenchymal Progenitor Cells Therapy for Knee Osteoarthritis
Study Type
Interventional

2. Study Status

Record Verification Date
September 2018
Overall Recruitment Status
Completed
Study Start Date
December 2015 (Actual)
Primary Completion Date
March 2018 (Actual)
Study Completion Date
March 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Cellular Biomedicine Group Ltd.
Collaborators
RenJi Hospital

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Evaluate the safety and efficacy of Allogenic Adipose Tissue-Derived Mesenchymal Progenitor Cells Therapy for Knee Osteoarthritis.
Detailed Description
A Phase I, Randomized, Single-centered, Double-blinded Clinical Trial of Allogenic Adipose Tissue-Derived Mesenchymal Progenitor Cells Therapy for Knee Osteoarthritis. This is a randomized,single-blind, double-blinded,phase I clinical trial. Subjects who are with a clinical diagnosis of knee osteoarthritis cartilage defects and will be randomly distributed 1:1:1 to different dosage group after signing the ICF and screening tests.The treatment will accept Allogenic ReJoinTM at the first and fourth week.The duration of the therapy is 48 weeks.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteoarthritis

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
22 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Mesenchymal progenitor cells Dosage 1
Arm Type
Other
Arm Description
Mesenchymal progenitor cells low-dose group
Arm Title
Mesenchymal progenitor cells Dosage 2
Arm Type
Other
Arm Description
Mesenchymal progenitor cells mid-dose group
Arm Title
Mesenchymal progenitor cells Dosage 3
Arm Type
Other
Arm Description
Mesenchymal progenitor cells high-dose group
Intervention Type
Biological
Intervention Name(s)
Mesenchymal progenitor cells
Intervention Description
Biological: Allogenic Adipose tissue-derived mesenchymal progentior cells administrated for intra-articular use
Primary Outcome Measure Information:
Title
Safety, recording of Adverse Events and Serious Adverse Events
Time Frame
12 weeks,48 weeks
Title
WOMAC Score
Time Frame
48 weeks
Secondary Outcome Measure Information:
Title
VAS Score
Time Frame
48 weeks
Title
SF-36
Time Frame
48 Weeks
Title
The volume of articular cartilage
Time Frame
48 weeks
Title
WORMS Score
Time Frame
48 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Object has an allergic history or is of an allergic constitution. Subjects who understand and sign the consent form for this study. Age: 18-70, males and females. Clinical diagnosis of degenerative arthritis by Radiographic Criteria of KellgrenLawrence:Duration of pain over Grade 4(11-point numeric scale)> 4 months. Course of Knee osteoarthritis:6 months to 10 years; The VAS score :3-8 points.(the data acquisition time is to stop using all analgesic at least 3 days ). Exclusion Criteria: The subject has an allergic history of medicine or food。. The subject'BMI is over 30. The subject has uncontrolled or hard-to-control diseases of cardiovascular, liver, kidney or lung, endocrine system. The subject has an history malignant tumour. The subject has complications or diseases of: systemic or rheumatoid arthritis, Chondrocalcinosis articularis, Hemochromatosis,inflammatory arthropathy,avascular necrosis of femoral head,Paget's disease,hemophilic arthropathy,infectional arthritis,Charcot's disease,villonodular synovitis or synovial chondromatosis. The subject has severe generalized infectious diseases or local knee infection in the 3 months prior to this trial. The subject has disease of lower limbs which may be interfered knee evaluation, for example fibromyalgia, osphyalgia, lumbar disc protrusion and so on. The subject has coagulation disorders. The subject has received arthroscopic surgery or intra-articular operations in the 6 months prior to this trial. The subject has received other intra-articular injections for KOA in the 6 months preceding the trial. The subject has received aminoglucose or chondroitin sulfate in the 6 months preceding the trial. The subject has plan of knee prosthesis within the trial. The subject has contraindication of MRI, included but not only: the subject installed heart pacemaker、defibrillator、heart bracket、heart valve prosthesis、metal clip after aneurysm surgery、drug infusion device implanted in vivo、any electronic device implanted in the body(nerve stimulator、bone growth stimulator)、endovascular coil、strainer、ECG monitor、metal suture、shrapnel or sand of body, plate fixation and steel nail after fracture - Page 4 of 4 [DRAFT] - surgery、artificial limb or joint、audiphone、artificial cochlea、middle ear shift plant、metallic intraocular foreign body etc; claustrophobia、pregnancy within 3 months、critically ill patients. The subject tests positive for: HIV, hepatitis virus, syphilis or other infectious diseases. The subject has history of alcoholism, drug abuse, or mental illness in the 3 years prior to this trial. The subject has participated in any other clinical trial in the 3 months prior to this trial. The subject is pregnant, lactating or planning to conceive within the next 6 months. The subject has any other unsuitable or adverse condition to be determined by the investigator.
Facility Information:
Facility Name
Department of Rheumatology,Ren Ji Hospital,School of Medicine,Shanghai Jiao Tong University,Shanghai,China
City
Shanghai
State/Province
Shanghai
ZIP/Postal Code
200127
Country
China

12. IPD Sharing Statement

Citations:
PubMed Identifier
31639063
Citation
Zhao X, Ruan J, Tang H, Li J, Shi Y, Li M, Li S, Xu C, Lu Q, Dai C. Multi-compositional MRI evaluation of repair cartilage in knee osteoarthritis with treatment of allogeneic human adipose-derived mesenchymal progenitor cells. Stem Cell Res Ther. 2019 Oct 21;10(1):308. doi: 10.1186/s13287-019-1406-7.
Results Reference
derived

Learn more about this trial

Clinical Trial of Allogenic Adipose Tissue-Derived Mesenchymal Progenitor Cells Therapy for Knee Osteoarthritis

We'll reach out to this number within 24 hrs